Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.32 |
| ▸ | CDK9 | P50750 | 5/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6533544 | 0.83 | VCP (0.33) | KDM5AKDM4CKDM5BIGF1RNOS2 | |
| SCHEMBL4096085 | 0.81 | KDM5A (0.35) | KDM5AKDM4CKDM5BCCNT1CDK9 | |
| SCHEMBL6531195 | 0.79 | MAPK8 (0.43) | CCNT1CDK9ACHE | |
| SCHEMBL4091386 | 0.77 | HRH4 (0.40) | CCNT1CDK9NOS2MAPK1 | |
| SCHEMBL5983913 | 0.71 | HCRTR1 (0.33) | IGF1RMAPK1VCPACHE | |
| SCHEMBL4095076 | 0.66 | NOS2 (0.40) | CCNT1CDK9NOS2MAPK1ACHE | |
| SCHEMBL4099608 | 0.65 | MAOB (0.42) | NOS2 | |
| SCHEMBL4089781 | 0.65 | MAOB (0.42) | NOS2 | |
| SCHEMBL4094568 | 0.65 | NOS2 (0.39) | IGF1RCCNT1CDK9NOS2MAPK1 | |
| SCHEMBL4103090 | 0.65 | ITGAL (0.40) | KDM5AKDM4CKDM5BVCPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | KDM5A 4190/4885KDM4C 3586/4885KDM5B 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.